OTHER INFORMATION
+Added: During the three months ended March 31, 2024, none of our directors or officers adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K.
EXHIBIT INDEX
2 unchanged sentences
3.2 Amendment to Articles of the Company (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the SEC on November 7, 2018).
−Removed: 10.1# Executive Employment Agreement, dated effective as of July 10, 2023, between Arbutus Biopharma, Inc.
−Removed: and Karen Sims, MD, PhD (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 3, 2023).
−Removed: 10.2# Executive Employment Agreement, dated effective as of July 10, 2023, between Arbutus Biopharma, Inc.
−Removed: Christopher Naftzger (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 3, 2023).
−Removed: 10.3# Option Agreement, dated July 10, 2023, by and between Arbutus Biopharma Corporation and J.
−Removed: Christopher Naftzger (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 3, 2023).
+Added: 10.1# Executive Employ ment Agreement, dated July 10, 2015, by and between the Company and Michael McElhaugh , as amended by the First Amendment to Executive Employment Agreement, dated April 20, 2016, the Second Amended to Executive Employment Agreement dated December 11, 20 18, the Third Amendment to Executive Employment Agreement dated November 1, 2022 and the Fourth Amendment to the Executive Employment Agreement, dated January 1, 2024 (incorporated her ein by reference to Exhibit 10.23 of the Registrant ’ s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 5, 2024).
31.1* Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: 101 The following materials from Arbutus Biopharma Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in inline XBRL (eXtensible Business Reporting Language):
+Added: 101 The following materials from Arbutus Biopharma Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in inline XBRL (eXtensible Business Reporting Language):
(i) Condensed Consolidated Balance Sheets;
8 unchanged sentences
# Management contract or compensatory arrangement.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on November 7, 2023.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on May 2, 2024.
ARBUTUS BIOPHARMA CORPORATION
−Removed: /s/ William H.
−Removed: President and Chief Executive Officer
+Added: /s/ Michael J.
+Added: Interim President and Chief Executive Officer
(Principal Executive Officer)
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.